NASDAQ$ELVN

Enliven Therapeutics Inc · Q2 2024 earnings

Q2 2024 earnings · · After market close · Investor relations

Reports in 4 weeks

Enliven Therapeutics hasn't published Q2 2024 actuals yet. The tiles below frame what to compare against; sections further down are historical context only.

  • Most recent report

    Q4 2025

    Revenue
    $0.00
    EPS
    -$0.48
  • Year-ago · Q2 2023

    Q2 2023

    Revenue
    EPS
    -$0.41
  • FY2024 consensus

    Analyst consensus

    Revenue
    $0.00
    EPS
    -$1.95

Revenue & EPS history

Enliven Therapeutics · Revenue · Quarterly

$0

Q4 2025

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports

Historical avg

-0.4%

Avg return

Earnings day

+2.4%

Avg return

5 days after

+7.4%

Avg return

30 days after

48%

11 / 23 earnings

Positive

+17.6%

Q2 2020

Best reaction

-22.5%

Q4 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+4.3%+3.4%+35.1%
Q3 2025-0.3%+11.3%-16.9%
Q2 2025-0.8%-1.1%-0.1%
Q1 2025+0.4%+19.7%+29.3%
Q4 2024-3.5%-7.7%-14.6%
Q3 2024-8.3%-8.4%-14.8%
Q1 2024-2.0%-5.9%-10.1%
Q4 2023-2.4%+43.0%+71.8%
Q3 2023-9.3%-12.4%-4.5%
Q2 2023-2.0%-8.0%-7.1%
Q1 2023-2.4%-0.3%+8.8%
Q4 2022+2.1%+4.5%+2.6%
Q3 2022+0.4%-5.5%-1.3%
Q2 2022+2.5%-1.7%-3.4%
Q1 2022-6.1%-11.5%-12.2%
Q4 2021+11.1%+22.2%-27.8%
Q3 2021+0.8%-3.8%-20.2%
Q2 2021+0.3%-18.0%-14.5%
Q1 2021+12.8%+15.8%+27.3%
Q4 2020-22.5%-19.5%-31.7%
Q3 2020-3.4%+13.9%+57.0%
Q2 2020+17.6%+19.8%+8.1%
Q1 2020+1.1%+4.4%+108.5%
Q4 2019
Q3 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro